Cross-source evidence timeline

Pasireotide research timeline

Follow 63 selected, directly cited source records from October 17, 2012 through October 31, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

63Selected records
15Source years
3Evidence lanes
October 31, 2026Latest source date

Source year

2026

9 records
  1. Literature metadata

    Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas.↗

    PubMed lists PMID 42778805 in Pituitary as Journal Article, with publication-date metadata of 2026-09-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Pituitary acting drugs: cabergoline and pasireotide.↗

    PubMed lists PMID 35670988 in Pituitary as Journal Article, Review, with publication-date metadata of 2022-06-07 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Pasireotide: a review of its use in Cushing's disease.↗

    PubMed lists PMID 23605695 in Drugs as Journal Article, Review, with publication-date metadata of 2013-05 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT05928390↗

    PeptideScanner retained ClinicalTrials.gov record NCT05928390 at 2026-11-15T22:05:38.400Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  5. Literature metadata

    Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs.↗

    PubMed lists PMID 38713182 in Endocrine-related cancer as Journal Article, Multicenter Study, with publication-date metadata of 2024-05-27 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study.↗

    PubMed lists PMID 38577574 in Frontiers in endocrinology as Clinical Trial, Phase IV, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2024-03-21 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT06295952↗

    PeptideScanner retained ClinicalTrials.gov record NCT06295952 at 2026-11-15T22:05:38.400Z. Its registry update date was 2026-03-04, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  8. Literature metadata

    Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide.↗

    PubMed lists PMID 23228667 in Diabetes & metabolism as Journal Article, Review, with publication-date metadata of 2012-12-08 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.↗

    PubMed lists PMID 27473537 in Drugs as Journal Article, Review, with publication-date metadata of 2016-09 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2025

5 records
  1. Clinical trials

    ClinicalTrials.gov record NCT02713776↗

    PeptideScanner retained ClinicalTrials.gov record NCT02713776 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-12-19, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  2. Literature metadata

    Real-life data on pasireotide in monotherapy or combined in active Cushing's disease.↗

    PubMed lists PMID 41323967 in Frontiers in endocrinology as Journal Article, with publication-date metadata of 2025-11-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Real-World Experience with Pasireotide-LAR in Cushing's Disease: Single-Center 12-Month Observational Study.↗

    PubMed lists PMID 40283624 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2025-04-18 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT03847207↗

    PeptideScanner retained ClinicalTrials.gov record NCT03847207 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-02-19, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT06456359↗

    PeptideScanner retained ClinicalTrials.gov record NCT06456359 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-01-13, and PeptideScanner's reviewed identity mapping was pasireotide.↗

Source year

2024

7 records
  1. Clinical trials

    ClinicalTrials.gov record NCT02310269↗

    PeptideScanner retained ClinicalTrials.gov record NCT02310269 at 2026-11-15T22:05:38.400Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01794793↗

    PeptideScanner retained ClinicalTrials.gov record NCT01794793 at 2026-11-15T22:05:38.400Z. Its registry update date was 2024-10-01, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  3. Literature metadata

    Rapid Resolution of Recalcitrant Headache With Pasireotide in an Adult Patient With Acromegaly.↗

    PubMed lists PMID 39129819 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2024-08-09 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.↗

    PubMed lists PMID 32843370 in Clinical journal of the American Society of Nephrology : CJASN as Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-08-25 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review.↗

    PubMed lists PMID 39072348 in Diabetes, metabolic syndrome and obesity : targets and therapy as Journal Article, Review, with publication-date metadata of 2024-07-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    The Role of the GH Receptor Polymorphisms as a Prognostic Factor of Vertebral Fractures in Acromegalic Patients Resistant to First-generation SSAs and Treated with Pegvisomant or Pasireotide LAR.↗

    PubMed lists PMID 38982703 in Endocrine, metabolic & immune disorders drug targets as Journal Article, with publication-date metadata of 2024-07-05 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences.↗

    PubMed lists PMID 38817802 in Drugs in context as Journal Article, with publication-date metadata of 2024-05-20 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2023

1 record
  1. Literature metadata

    Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature.↗

    PubMed lists PMID 35518928 in Frontiers in endocrinology as Case Reports, Review, Journal Article, with publication-date metadata of 2022-04-19 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2022

6 records
  1. Literature metadata

    Second line treatment of acromegaly: Pasireotide or Pegvisomant?↗

    PubMed lists PMID 35931640 in Best practice & research. Clinical endocrinology & metabolism as Meta-Analysis, Journal Article, Review, with publication-date metadata of 2022-07-16 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.↗

    PubMed lists PMID 20463350 in The New England journal of medicine as Clinical Trial, Letter, Multicenter Study, with publication-date metadata of 2010-05-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma.↗

    PubMed lists PMID 25613083 in Investigational new drugs as Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, with publication-date metadata of 2015-01-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Pasireotide for the treatment of acromegaly.↗

    PubMed lists PMID 26808354 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2016-02-17 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.↗

    PubMed lists PMID 18957506 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Phase II, Journal Article, Multicenter Study, with publication-date metadata of 2008-10-28 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.↗

    PubMed lists PMID 24287689 in Pituitary as Case Reports, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-12 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2021

8 records
  1. Clinical trials

    ClinicalTrials.gov record NCT02215070↗

    PeptideScanner retained ClinicalTrials.gov record NCT02215070 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-11-17, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT03103009↗

    PeptideScanner retained ClinicalTrials.gov record NCT03103009 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-09-29, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00171730↗

    PeptideScanner retained ClinicalTrials.gov record NCT00171730 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-09-05, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT00171951↗

    PeptideScanner retained ClinicalTrials.gov record NCT00171951 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-06-02, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT01468532↗

    PeptideScanner retained ClinicalTrials.gov record NCT01468532 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-03-25, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT01270321↗

    PeptideScanner retained ClinicalTrials.gov record NCT01270321 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-02-17, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  7. Literature metadata

    Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies.↗

    PubMed lists PMID 26275531 in Investigational new drugs as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-08-16 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Pasireotide and mifepristone: new options in the medical management of Cushing's disease.↗

    PubMed lists PMID 24126229 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2014-01 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2020

5 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00446082↗

    PeptideScanner retained ClinicalTrials.gov record NCT00446082 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-12-21, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00698464↗

    PeptideScanner retained ClinicalTrials.gov record NCT00698464 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-12-21, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT01385956↗

    PeptideScanner retained ClinicalTrials.gov record NCT01385956 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-09-28, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT02775227↗

    PeptideScanner retained ClinicalTrials.gov record NCT02775227 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-08-24, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  5. Literature metadata

    How to Position Pasireotide LAR Treatment in Acromegaly.↗

    PubMed lists PMID 30608534 in The Journal of clinical endocrinology and metabolism as Journal Article, Review, with publication-date metadata of 2019-06-01 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2019

2 records
  1. Literature metadata

    Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.↗

    PubMed lists PMID 29534939 in Clinical genitourinary cancer as Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-02-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide.↗

    PubMed lists PMID 29396758 in Journal of endocrinological investigation as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2018-02-02 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2018

4 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01469572↗

    PeptideScanner retained ClinicalTrials.gov record NCT01469572 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-10-18, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01137682↗

    PeptideScanner retained ClinicalTrials.gov record NCT01137682 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-04-05, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT02527993↗

    PeptideScanner retained ClinicalTrials.gov record NCT02527993 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-03-07, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT02021942↗

    PeptideScanner retained ClinicalTrials.gov record NCT02021942 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-02-05, and PeptideScanner's reviewed identity mapping was pasireotide.↗

Source year

2017

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01637272↗

    PeptideScanner retained ClinicalTrials.gov record NCT01637272 at 2026-11-15T22:05:38.400Z. Its registry update date was 2017-05-10, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01356862↗

    PeptideScanner retained ClinicalTrials.gov record NCT01356862 at 2026-11-15T22:05:38.400Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was pasireotide.↗

Source year

2016

4 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00804336↗

    PeptideScanner retained ClinicalTrials.gov record NCT00804336 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-10-19, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01620138↗

    PeptideScanner retained ClinicalTrials.gov record NCT01620138 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-08-22, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT01488487↗

    PeptideScanner retained ClinicalTrials.gov record NCT01488487 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-04-07, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT00434148↗

    PeptideScanner retained ClinicalTrials.gov record NCT00434148 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-03-08, and PeptideScanner's reviewed identity mapping was pasireotide.↗

Source year

2015

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT02622906↗

    PeptideScanner retained ClinicalTrials.gov record NCT02622906 at 2026-11-15T22:05:38.400Z. Its registry update date was 2015-12-07, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  2. Regulatory

    Federal Register notice 2015-10994↗

    The Federal Register published notice 2015-10994, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; SIGNIFOR,” and PeptideScanner's exact reviewed identity mapping connects the document to Pasireotide.↗

Source year

2014

5 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01128192↗

    PeptideScanner retained ClinicalTrials.gov record NCT01128192 at 2026-11-15T22:05:38.400Z. Its registry update date was 2014-12-25, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  2. Literature metadata

    Pasireotide for the treatment of Cushing's disease.↗

    PubMed lists PMID 20533892 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2010-07 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Pasireoride (Signifor) for Cushing's disease.↗

    PubMed lists PMID 23669783 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2013-05-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Assessment of the absorption, metabolism and excretion of [¹⁴C]pasireotide in healthy volunteers using accelerator mass spectrometry.↗

    PubMed lists PMID 23680921 in Cancer chemotherapy and pharmacology as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-05-17 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience.↗

    PubMed lists PMID 25003365 in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2014-07-08 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2013

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT01895296↗

    PeptideScanner retained ClinicalTrials.gov record NCT01895296 at 2026-11-15T22:05:38.400Z. Its registry update date was 2013-07-10, and PeptideScanner's reviewed identity mapping was pasireotide.↗

Source year

2012

2 records
  1. Regulatory

    Drugs@FDA application NDA200677↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 200677 with status AP dated 2012-12-14, and names pasireotide diaspartate among the application record's active ingredients.↗

  2. Regulatory

    Federal Register notice 2012-25483↗

    The Federal Register published notice 2012-25483, attributed to FDA and its parent HHS department, on 2012-10-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Pasireotide.↗